glp 1 mayo clinic Why do some people lose substantial weight with GLP-1-based medications while others see more modest results? A study offers a potential answer by identifying a distinct biological subtype mayo clinic glp 1 oral
Description
Research Status and Future Directions GLP-1 agonists are FDA-approved, widely prescribed medications with extensive safety and efficacy data
The variability in individual responses to semaglutide highlights the need for a tailored approach
For most patients, GLP-1 agonists represent safe and effective treatment options
September 2022
This equates to just a little less than 20kg per person per year, close to the global average but a little below levels seen in countries like the UK (25-30kg per person per year)
